Rexulti (brexpiprazole) is expensive primarily because it is still protected by patents that block generic competition. A 30-day supply typically costs over $1,000 without insurance in the United States, putting it among the pricier medications in its class. Several overlapping factors keep the price high, but patent exclusivity is the biggest one.
Patent Protection Blocks Generic Competition
The single most important reason for Rexulti’s price is that its manufacturer, Otsuka Pharmaceutical, holds active patents that prevent other companies from selling cheaper versions. FDA records show key patents on Rexulti extending through October 2032 for most tablet strengths (0.25 mg, 0.5 mg, 1 mg, 2 mg, and 3 mg). One patent covering the 4 mg tablet has an earlier expiration of April 2026, but the core formulations remain locked down for years.
While the FDA has technically approved a generic version of brexpiprazole, approval alone doesn’t put a product on pharmacy shelves. As long as these patents remain enforceable, generic manufacturers cannot legally launch their products. This is the same dynamic that keeps many brand-name psychiatric medications expensive: without competition, there is no downward pressure on price. Once those patents expire and generics actually reach the market, you can expect the cost to drop significantly, as it did when Abilify (aripiprazole) lost patent protection.
An Expanding Label Justifies the Investment
Rexulti was originally approved in 2015 as an add-on treatment for major depressive disorder and for schizophrenia. In 2023, it became the first drug approved by the FDA to treat agitation associated with Alzheimer’s dementia. That new indication required two separate 12-week randomized, placebo-controlled clinical trials, each enrolling a vulnerable patient population that demands careful, costly study design.
Pharmaceutical companies price brand-name drugs to recover not just the cost of the trials that succeeded but also the many that didn’t. Expanding into Alzheimer’s-related agitation gave Otsuka a broader market for Rexulti, but it also represented a major financial bet. The pricing reflects the expectation that the company needs to recoup those investments during the remaining years of patent exclusivity.
How Rexulti Compares to Alternatives
One question worth asking is whether a cheaper medication could work instead. Aripiprazole (generic Abilify) is the closest relative to brexpiprazole. Both are atypical antipsychotics that work through similar mechanisms in the brain, and generic aripiprazole is available for a fraction of brand-name Rexulti’s U.S. price.
A Canadian pharmacoeconomic review found that, at recommended doses, the annual cost of brexpiprazole and aripiprazole were actually comparable in that country’s pricing system, with aripiprazole costing slightly more in some dose ranges. But those figures used Ontario’s drug formulary prices, where government negotiation keeps costs lower across the board. In the U.S., where no such negotiation exists for most commercial plans, the gap between brand-name Rexulti and generic aripiprazole is enormous. If your doctor prescribed Rexulti specifically because you didn’t respond well to aripiprazole or experienced side effects, the switch may not be straightforward. But it’s a conversation worth having if cost is a barrier.
Why U.S. Prices Are Higher Than Other Countries
The U.S. pharmaceutical market lacks the government price controls found in Canada, the U.K., and most of Europe. Manufacturers set their own list prices, and while insurance companies negotiate discounts, the starting price is still far higher than what patients in other countries pay for the same pill. This structural difference affects every brand-name drug, but it hits medications like Rexulti especially hard because there’s no generic alternative available yet to force competition.
Financial Assistance Options
If you’re struggling with the cost, there are a few routes to explore. Otsuka runs a patient assistance program through the Otsuka Patient Assistance Foundation (OPAF), a nonprofit that provides Rexulti for free to eligible patients who are uninsured or underinsured. Eligibility is based on household income, and you’ll need to submit proof such as a tax return, W-2, pay stubs, or a Social Security award letter. U.S. citizenship is not required.
For insured patients, the foundation performs a benefit verification. If your coverage is insufficient, they may still qualify you with additional documentation like a prior authorization denial letter or an explanation of benefits from your insurer. If the online eligibility tool suggests you don’t qualify, OPAF recommends calling their advocates directly at 1-855-727-6274 to discuss your specific situation, as individual circumstances sometimes change the outcome.
Beyond the manufacturer’s program, copay cards (typically for commercially insured patients) and independent nonprofit foundations that cover mental health medications can also reduce out-of-pocket costs. Your prescriber’s office or pharmacist can often point you toward these resources quickly.
When Prices Will Likely Drop
The clearest path to lower Rexulti prices is generic entry. With the main patents running through October 2032, most tablet strengths won’t see generic competition until 2033 at the earliest, assuming no legal challenges or settlements move that date earlier. The 4 mg tablet has a patent expiring in April 2026, which could see earlier generic availability for that specific dose. Once generics do launch, history suggests prices could fall by 80% or more within a few years, as happened with aripiprazole after Abilify lost exclusivity in 2015.